Novan (NASDAQ:NOVN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Novan (NASDAQ:NOVN) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Novan Stock Performance

NOVN stock opened at $0.00 on Tuesday. Novan has a fifty-two week low of $0.08 and a fifty-two week high of $3.33. The company has a market cap of $22,412.00, a P/E ratio of 0.00 and a beta of -0.06.

Novan Company Profile

Novan, Inc, a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.